Boundless Bio, Inc. (BOLD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.4 |
| Open | 2.38 |
| Day High | 2.75 |
| Day Low | 2.25 |
| 52-Week High | 2.75 |
| 52-Week Low | 0.96 |
| Volume | 65.08M |
| Average Volume | 225,540 |
| Market Cap | 58.41M |
| PE | -1.04 |
| EPS | -2.49 |
| Moving Average 50 Days | 1.47 |
| Moving Average 200 Days | 1.27 |
| Change | 1.2 |
Boundless Bio to Participate in the Leerink Global Healthcare Conference
GlobeNewswire Inc.
Mar 04, 2026 12:00 PM GMT
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene am
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amp
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
GlobeNewswire Inc.
Jan 20, 2026 12:00 PM GMT
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second half of 2028 SAN DIEGO, Jan. 20,